Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation.

Leksa, Vladimir; Loewe, Robert; Binder, Brigitte; Schiller, Herbert B; Eckerstorfer, Paul; Forster, Florian; Soler-Cardona, Ana; Ondrovicová, Gabriela; Kutejová, Eva; Steinhuber, Eva; Breuss, Johannes; Drach, Johannes; Petzelbauer, Peter; Binder, Bernd R; Stockinger, Hannes

Leksa, Vladimir; Loewe, Robert; Binder, Brigitte; Schiller, Herbert B; Eckerstorfer, Paul; Forster, Florian; Soler-Cardona, Ana; Ondrovicová, Gabriela; Kutejová, Eva; Steinhuber, Eva; Breuss, Johannes; Drach, Johannes; Petzelbauer, Peter; Binder, Bernd R; Stockinger, Hannes.

Affiliation

Leksa V; Molecular Immunology Unit, Pathophysiology, Infectiology & Immunology, Medical University of Vienna, Austria. vladimir.leksa@meduniwien.ac.at

Circ Res ; 108(6): 676-85, 2011 Mar 18.

Article in En | MEDLINE | ID: mdl-21273553

Subject(s)

ADAM Proteins/metabolism; Cell Movement/physiology; Endothelial Cells/physiology; Neovascularization, Physiologic/physiology; Plasminogen/metabolism; Receptor, IGF Type 2/metabolism; Urokinase-Type Plasminogen Activator/metabolism; ADAM17 Protein; Animals; Cells, Cultured; Chimera; Growth; Humans; Melanoma/blood supply; Melanoma/pathology; Melanoma/physiopathology; Mice; Neovascularization, Pathologic/physiopathology; Receptor, IGF Type 2/chemistry; Receptors, Urokinase Plasminogen Activator/metabolism; Solubility; Umbilical Veins

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Plasminogen / Urokinase-Type Plasminogen Activator / Cell Movement / Receptor, IGF Type 2 / Neovascularization, Physiologic / Endothelial Cells / ADAM Proteins Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Circ Res Year: 2011 Type: Article Affiliation country: Austria

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google